Transaction in Own Shares

Summary by AI BETAClose X

CVS Group plc has announced the purchase of 107,761 ordinary shares between September 1st and September 4th, 2026, as part of its ongoing share buyback program. These shares were acquired from Joh. Berenberg, Gossler & Co. KG, London Branch, at prices ranging from 1,273.00 pence to 1,322.00 pence, with a volume-weighted average price of 1,299.03 pence. The company intends to cancel these shares, which will result in 67,862,629 ordinary shares outstanding and no shares held in treasury. Since the buyback program began, CVS has repurchased a total of 2,300,470 ordinary shares.

Disclaimer*

CVS Group plc
07 September 2026
 
07 September 2026

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

Transaction in own shares

 

CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").

 

Date of purchases:

01/09/2026 - 04/09/2026

Aggregate number of Ordinary Shares purchased:

107,761

Lowest price paid per share (GBp):

1,273.00

Highest price paid per share (GBp):

1,322.00

Volume weighted average price paid per share (GBp):

1,299.03

 

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 67,862,629 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 67,862,629 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 2,300,470 Ordinary Shares in aggregate at a weighted average price of 1,251.3 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, (a full breakdown of the individual trades made by Berenberg as part of the Share Buyback Programme is attached to this announcement:


http://www.rns-pdf.londonstockexchange.com/rns/5574T_1-2026-9-4.pdf

 

Contacts

CVS Group plc                                                                                                                                                       via FGS Global

Richard Fairman, Chief Executive Officer

Robin Alfonso, Chief Financial Officer

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

FGS Global                                                                                               

Faeth Birch                                                                                                                                                      +44 (0)207 251 3801

Charlie Chichester                                                                                                                                    cvsgroup@fgsglobal.com

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

CVS Group (CVSG)
UK 100

Latest directors dealings